Journal article
Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada*
Abstract
OBJECTIVE: To study the impact of the Risk-Scoring Tool (RST) as a strategy for targeting prophylaxis effectively in 33-35-week gestational age (GA) Canadian infants who range from low to high risk by evaluating the subsequent incidence of respiratory syncytial virus (RSV) infections resulting in emergency room (ER) visits and hospitalization.
DESIGN: Prospective, descriptive study.
Authors
Paes B; Steele S; Janes M; Pinelli J
Journal
Current Medical Research and Opinion, Vol. 25, No. 7, pp. 1585–1591
Publisher
Taylor & Francis
Publication Date
July 1, 2009
DOI
10.1185/03007990902929112
ISSN
0300-7995
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AlgorithmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCanadaCase-Control StudiesFemaleGestational AgeHumansInfant, NewbornInfant, PrematureMalePalivizumabResearch DesignRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRisk AssessmentRisk Factors